Watch Ticker

Alnylam Pharmaceuticals, Inc.

Go to Alnylam Pharmaceuticals, Inc. Website

$401.80

9.56 (2.44%)

Live

Previous Close

$401.8

Day Range

$382.19 - $401.8

Previous Day Range

$350 - $402.4313

Market Cap

$52.7 billion USD

Day Vol.

1.8 million

Previous Day Vol.

3.4 million

Currency

USD

Primary Exchange

Nasdaq

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the m...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Vandana Singh - Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Alnylam Pharmaceuticals reported strong Q2 earnings, beating analyst expectations with $773.69 million in revenue and raising fiscal 2025 sales guidance. The company's drug Amvuttra for ATTR-CM has reached 1,400 patients, adding approximately $150 million in revenue.

Related tickers: ALNY.

Read Full Article

Vandana Singh - Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

Alnylam Pharmaceuticals reported strong Q2 earnings, with sales rising 17% to $773.69 million, exceeding analyst estimates. The company raised its 2025 revenue guidance by 27% and showed significant growth in its TTR and Rare disease product revenues.

Related tickers: ALNY, MRNA.

Read Full Article

Trending Tickers

Please sign in to view